Cent Eur J Public Health 2011, 19(4):190-196 | DOI: 10.21101/cejph.a3656
Follow-up of a Cardiovascular Prevention Campaign
- Department of Family Medicine, University of Brussels (VUB), Brussels, Belgium
The aim of this study was to evaluate the cardiovascular risk (CVR) factors and morbidity in a sample of the population that received a brief intervention on cardiovascular prevention seven years ago. All family physicians who participated in the Cardiovascular Prevention Campaign in five Belgian towns in 2002-2003 received a follow-up questionnaire for each participating patient. The questionnaire included questions about new cardiovascular diagnoses, parameters of the latest physical examination and blood tests. Analyses were based on the 318 questionnaires that included essential information such as the date of the latest contact and the new diagnosis or mortality. The proportion of patients with a low CVR decreased from 75% in 2002-2003 to 40% in 2010. Participants showed a significant increase of the abdominal circumference, triglycerides and fasting glycaemia. Only LDL-cholesterol levels decreased significantly (p=0.002). Four percent of the patients died, more male (7%) than female (2%) (p=0.03). One in ten patients presented with a cardiovascular event. Most of the changes are probably attributable to age. It is clear that the long-term effect of a brief intervention only followed by usual care is not sufficient to attain optimal level of cardiovascular prevention.
Keywords: cardiovascular risk, hypertension, cholesterol, diabetes, mortality
Received: December 6, 2010; Revised: August 12, 2011; Accepted: August 12, 2011; Published: December 1, 2011 Show citation
ACS | AIP | APA | ASA | Harvard | Chicago | Chicago Notes | IEEE | ISO690 | MLA | NLM | Turabian | Vancouver |
References
- Lloyd-Williams F, O'Flaherty M, Mwatsama M, Birt C, Ireland R, Capewell S. Estimating the cardiovascular mortality burden attributable to the European Common Agricultural Policy on dietary saturated fats. Bull World Health Organ [Internet]. 2008 [cited 2010 May 15];86(7). Available from: http://www.who.int/bulletin/volumes/86/7/08-053728/en/index.html.
Go to original source...
Go to PubMed...
- Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al.; European Society of Cardiology (ESC) Committee for Practice Guidelines (CPG). European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). Eur Heart J. 2007 Oct;28(19):2375414.
- Khan NA, Hemmelgarn B, Herman RJ, Bell CM, Mahon JL, Leiter LA, et al.; Canadian Hypertension Education Program. The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2-therapy. Can J Cardiol. 2009 May;25(5):287-98.
Go to original source...
- Kostis JB. The importance of managing hypertension and dyslipidemia to decrease cardiovascular disease. Cardiovasc Drugs Ther. 2007 Aug;21(4):297-309.
Go to original source...
Go to PubMed...
- Roccatagliata D, Avanzini F, Monesi L, Caimi V, Lauri D, Longoni P, et al.; Collaborative Group Risk and Prevention Study. Is global cardiovascular risk considered in current practice? Treatment and control of hypertension, hyperlipidemia, and diabetes according to patients' risk level. Vasc Health Risk Manag. 2006;2(4):507-14.
Go to original source...
Go to PubMed...
- Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U; EUROASPIRE Study Group. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil. 2009 Apr;16(2):121-37.
Go to original source...
Go to PubMed...
- Boland B, Christiaens T, Goderis G, Govaerts F, Philips H, Smeets F, et al. Global cardiovascular risk. Huisarts Nu. 2007;36(7):339-69. (In Dutch.)
- Dahlöf B. Cardiovascular disease risk factors: epidemiology and risk assessment. Am J Cardiol. 2010 Jan 4;105(1 Suppl):3A-9A.
Go to original source...
Go to PubMed...
- Wood D; Joint European Societies Task Force. Established and emerging cardiovascular risk factors. Am Heart J. 2001 Feb;141(2 Suppl):S49-57.
Go to original source...
Go to PubMed...
- Devroey D, Kartounian J, Vandevoorde J, Betz W, Cogge M, De Man B, et al. Primary prevention of coronary heart disease in general practice: a cross sectional population study. Int J Clin Pract. 2004 Feb;58(2):130-8.
Go to original source...
Go to PubMed...
- Engberg M, Christensen B, Karlsmose B, Lous J, Lauritzen T. General health screenings to improve cardiovascular risk profiles: a randomized controlled trial in general practice with 5-year follow-up. J Fam Pract. 2002 Jun;51(6):546-52.
- vanWeel C, Bakx C, van den Hoogen H,ThienT, van den BoschW. Longterm outcome of cardiovascular prevention: a NijmegenAcademic Family Practices Network study. JAm Board Fam Med. 2006 Jan-Feb;19(1):62-8.
Go to original source...
- Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972 Jun;18(6):499-502.
Go to original source...
- De Cort P, Christiaens T, Philips H, Goossens M, Van Royen P. Hypertension. Huisarts Nu. 2009;38(9):340-61. (In Dutch.)
- Wens J, Sunaert P, Nobels F, Feyen L, Van Crombrugge P, Bastiaens H, et al. Diabetes mellitus type 2. Huisarts Nu. 2005;34(2):1-52.
- Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al.; Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). European guidelines on cardiovascular disease prevention in clinical practice: full text. Eur J Cardiovasc Prev Rehabil. 2007 Sep;14 Suppl 2:S1-113.
Go to original source...
Go to PubMed...
- World Health Organization. Prevention of cardiovascular disease: pocket guidelines for assessment and management of cardiovascular risk. Geneva: WHO; 2007.
- Conroy RM, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al.; SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003 Jun;24(11):987-1003.
Go to original source...
- Rasbash J, Steele F, Browne WJ, Goldstein H. A user's guide to MlwiN: version 2.10. Bristol: Centre for Multilevel Modelling, University of Bristol; 2009.
- Cacoub P, Tocque-Le Gousse E, Fabry C, Hermant S, Petzold L. Application in general practice of treatment guidelines for patients with dyslipidaemia: the RESPECT study. Arch Cardiovasc Dis. 2008 NovDec;101(11-12):715-21.
Go to original source...
Go to PubMed...
- Carroll MD, Lacher DA, Sorlie PD, Cleeman JI, Gordon DJ, Wolz M, et al. Trends in serum lipids and lipoproteins of adults, 1960-2002. JAMA. 2005 Oct 12;294(14):1773-81.
Go to original source...
Go to PubMed...
- van Dijk L, Otters HB, Schuit AJ. Moderately overweight and obese patients in general practice: a population based survey. BMC Fam Pract. 2006 Jul 7;7:43.
Go to original source...
Go to PubMed...
- Moreau M, Valente F, Mak R, Pelfrene E, de Smet P, De Backer G, et al. Obesity, body fat distribution and incidence of sick leave in the Belgian workforce: the Belstress study. Int J Obes Relat Metab Disord. 2004 Apr;28(4):574-82.
Go to original source...
Go to PubMed...
- Van Royen P, Bastiaens H, D'Hondt A, Provoost C, Van den Borght W. Overweight and obesity in adults in primary care. Huisarts Nu. 2006;35(3):118-40. (In Dutch.)
Go to original source...
Go to PubMed...
- Tuomilehto J. Impact of age on cardiovascular risk: implications for cardiovascular disease management.Atheroscler Suppl. 2004 May;5(2):9-17.
Go to original source...
Go to PubMed...
- National Institute for Health and clinical excellence (NHC). Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease [Internet]. London: NHC; 2008 [cited 2010 Apr 25]. Available from: http://www.nice.org.uk/nicemedia/pdf/CG67NICEguideline.pdf.
- Kostis JB. The importance of managing hypertension and dyslipidemia to decrease cardiovascular disease. Cardiovasc Drugs Ther. 2007 Aug;21(4):297-309.
Go to original source...
Go to PubMed...
- Ghandehari H, Kamal-Bahl S, Wong ND. Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003-2004. Am Heart J. 2008 Jul;156(1):112-9.
Go to original source...
Go to PubMed...
- Black HR. Optimal blood pressure: how low should we go? Am J Hypertens. 1999 Nov;12(11 Pt 2):113S-20S.
Go to original source...
- Hyman DJ, Pavlik VN. Self-reported hypertension treatment practices among primary care physicians: blood pressure thresholds, drug choices, and the role of guidelines and evidence-based medicine.Arch Intern Med. 2000 Aug 14-28;160(15):2281-6.
Go to original source...
- Janus ED, Bunker SJ, Kilkkinen A, Mc Namara K, Philpot B, Tideman P, et al. Prevalence, detection and drug treatment of hypertension in a rural Australian population: the Greater Green Triangle risk factor study 2004-2006. Intern Med J. 2008 Dec;38(12):879-86.
Go to original source...
Go to PubMed...
- Alvarsson M, Hilding A, Ostenson CG. Factors determining normalization of glucose intolerance in middle-aged Swedish men and women: a 8-10-year follow-up. Diabet Med. 2009 Apr;26(4):345-53.
Go to original source...
Go to PubMed...
- Ylihärsilä H, Lindström J, Eriksson JG, Jousilahti P, Valle TT, Sundvall J, et al. Prevalence of diabetes and impaired glucose regulation in 45- to 64-year-old individuals in three areas of Finland. Diabet Med. 2005 Jan;22(1):88-91.
Go to original source...
Go to PubMed...